BiotechTube
Stromal Therapeutics

Stromal Therapeutics

Basel, Switzerland· Est.
stromaltherapeutics.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Stromal Therapeutics is an early-stage, privately-held biotech company pioneering a novel approach to treating chronic inflammatory diseases by targeting the tissue stroma. Its platform focuses on locally acting, druggable tissue cytokines, with an initial application in inflammatory heart disease, where no specific therapies currently exist. The company has secured non-dilutive bridge funding from Swiss accelerators BaseLaunch and USZ Innovation to advance its lead candidate towards clinical development, leveraging the strong academic and clinical expertise of its founders.

Inflammatory Heart DiseaseChronic Inflammatory Diseases

Technology Platform

Platform focused on developing immunotherapies that target tissue cytokines and their inhibitors produced by stromal cells, aiming for localized modulation of inflammation at the disease site.

Funding History

2
Total raised:$15M
Series A$12M
Seed$3M

Opportunities

The primary opportunity is addressing the complete lack of approved therapies for specific inflammatory heart diseases, offering a clear path as a first-in-class treatment.
Success in this initial indication would validate the broader platform for application in larger chronic inflammatory markets, such as arthritis or fibrosis.

Risk Factors

High risk of preclinical-to-clinical translation failure for its novel stromal-targeting mechanism.
The company faces significant financial risk due to its reliance on limited bridge funding and the need to secure a major Series A round.
Pipeline concentration risk is extreme with only one disclosed asset.

Competitive Landscape

Competition in the broad immunology space is intense, dominated by large pharma with systemic biologic therapies. However, Stromal's niche focus on tissue-specific stromal cytokines in cardiac inflammation is relatively novel, providing initial competitive shelter. Long-term, it may compete with other companies exploring tissue-resident immunity and stromal biology.

More companies in Switzerland →